AstraZeneca could have a viable vaccine by November
The week started with good news from the US Food and Drug Administration (#FDA). The federal agency issued an “emergency use authorization” (EUA) for convalescent plasma to be used as a treatment for hospitalized #COVID-19 cases.
According to the FDA, there is enough scientific evidence that showed that the antibody-rich plasma “may be effective,” and the possible benefits outweigh the potential risks. "Today’s action follows the FDA’s extensive review of the science and data generated over the past several months stemming from efforts to facilitate emergency access to convalescent plasma for patients as clinical trials to definitively demonstrate safety and efficacy remain ongoing."
This EUA will facilitate the distribution of convalescent plasma in the States and its use by healthcare providers.
Ahead of the presidential elections, this is seen as a victory for the Trump administration. Related to the subject, President #Trump is considering fast-tracking AstraZeneca’s COVID-19 vaccine candidate. He wants it done and available to Americans before the election.
AstraZeneca’s potential #vaccine produced a “strong immune response” during the first two phases of clinical trials. Currently, it has advanced to Phase III trials.
Following the announcement, the company's stock price rose by nearly 4%.
Sources: marketwatch.com, thestreet.com
This information is prepared for general circulation. It does not regard to the specific investment objectives, financial situation or the particular needs of any recipient.
You should independently evaluate each financial product and consider the suitability of such a financial product, by taking into account your specific investment objectives, financial situation or particular needs, and by consulting an independent financial adviser as needed, before dealing in any financial products mentioned in this document.
This information may not be published, circulated, reproduced or distributed in whole or in part to any other person without the Company’s prior written consent. Past performance is not always indicative of likely or future performance. Any views or opinions presented are solely those of the author and do not necessarily represent those of za.capex.com